mutant ythdf1 (Addgene inc)
Structured Review

Mutant Ythdf1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutant ythdf1/product/Addgene inc
Average 93 stars, based on 14 article reviews
Images
1) Product Images from "RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m 6 A-Dependent Oncogenic Translation and Colorectal Tumorigenesis"
Article Title: RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m 6 A-Dependent Oncogenic Translation and Colorectal Tumorigenesis
Journal: Cancer Research
doi: 10.1158/0008-5472.CAN-23-2081
Figure Legend Snippet: Epi-Drug CRISPR dropout screens identify RUVBL1/2 as vulnerabilities of YTHDF1-expressing colorectal cancer cells. A, Composition of Epi-Drug sgRNA library and the workflow of CRISPR-Cas9 screens to identify YTHDF1-dependent vulnerabilities in colorectal cancer cells. B, Principal component analysis (PCA) of sgRNA abundances in each group at the end point of CRISPR-Cas9 screening. C, Left, top depleted genes in YTHDF1-overexpressing DLD1 cells vs. control vector (log 2 (fold change) < −0.5; log 10 ( P value < −1). Middle, top enriched genes in shYTHDF1 cells vs. shControl (log 2 (fold change) > 0.5; log 10 ( P value < −1). Right, overlapping of outlier genes identified the common candidates preferentially essential in a YTHDF1-dependent fashion. D and E, RUVBL1/2 mRNA expression in colorectal cancer cells compared with adjacent normal tissues in Hong Kong ( D ) and TCGA ( E ) colorectal cancer cohorts. In Hong Kong cohort, mRNA expression was normalized to β-actin. F, RUVBL1/2 and YTHDF1 proteins are overexpressed in colorectal cancer cells compared with paired adjacent normal tissues. G, Left, representative images of YTHDF1, RUVBL1, and RUVBL2 staining in colorectal cancer tissue microarrays ( N = 184). Right, Pearson correlation analysis of YTHDF1, RUVBL1, and RUVBL2 protein expression. H, Left, Kaplan–Meier curve analysis of RUVBL1 protein expression and patient survival in colorectal cancer in tissue microarray cohort ( N = 184). Right, multivariate Cox regression analysis. RUVBL1-low, IHC score 1; RUVBL1-high, IHC score 2 to 3. I, Left, Kaplan–Meier curve analysis of RUVBL2 protein expression and colorectal cancer patient survival. Right, multivariate Cox regression analysis. RUVBL2-low, IHC score 1 to 2; RUVBL2-high, IHC score 3. Paired t test ( D and E ; left), Student t -test ( E ; right), Pearson χ 2 test ( G ), or log rank test ( H and I ).
Techniques Used: CRISPR, Expressing, Control, Plasmid Preparation, Staining, Microarray
Figure Legend Snippet: RUVBL1/2 knockout abolishes oncogenic function of YTHDF1 in vitro and in vivo . A–D, Effect of RUVBL1/2 knockout on vector- and YTHDF1-overexpressing DLD1 and HCT116 cell proliferation ( N = 10; A ), colony formation ( N = 3, 7–14 days; B ), apoptosis ( N = 3; C ), and G 1 -S cell cycle transition ( N = 3; D ). E, Western blot of cell cycle and apoptosis markers. F, Representative brightfield images of primary colorectal cancer tumor-derived organoids expressing vector or YTHDF1, with or without RUVBL1/2 knockout. G, Effect of RUVBL1/2 knockout on vector- and YTHDF1-overexpressing DLD1 and HCT116 xenografts in nude mice. RUVBL1/2 abrogated differential growth between vector- and YTHDF1-overexpresing xenografts (DLD1, N = 5; HCT116, N = 8). Two-way ANOVA ( A ) and one-way ANOVA ( B–D and G ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Techniques Used: Knock-Out, In Vitro, In Vivo, Plasmid Preparation, Western Blot, Derivative Assay, Expressing
Figure Legend Snippet: YTHDF1 directly targets m 6 A-modified RUVBL1/2 mRNA methylation and promotes their protein expression in vitro and in vivo . A, UCSC snapshots of m 6 A-seq reads of RUVBL1/2 mRNA in DLD1 cells. The normalized read densities are shown for m 6 A (orange) and input (blue). B, Methylated RIP-qPCR analysis of m 6 A-modified RUVBL1/2 mRNA in DLD1 and HCT116 cells. C, RIP-qPCR with anti-YTHDF1 antibody showed binding of YTHDF1 to RUVBL1/2 mRNA, whereas mutant YTHDF1 (K395A, Y397A) had attenuated binding. D and E , Effect of YTHDF1 overexpression ( D ) or knockdown ( E ) on RUVBL1/2 mRNA and protein expression in DLD1 and HCT116 cells. F, Effect of YTHDF1 overexpression on RUVBL1/2 protein expression in primary colorectal cancer organoids PDO828 and PDO74. G, Expression of YTHDF1 and RUVBL1/2 in intestinal-specific Ythdf1 knockin mice (Ythdf1 lsl Cdx2-Cre ERT2 ) as compared with wildtype mice. Student t test ( B–D ) and one-way ANOVA ( E ). ****, P < 0.0001.
Techniques Used: Modification, Methylation, Expressing, In Vitro, In Vivo, Binding Assay, Mutagenesis, Over Expression, Knockdown, Knock-In
Figure Legend Snippet: YTHDF1 promotes translation efficiency of RUVBL1/2, which in turn interact with YTHDF1 and translational initiation factors. A, RNC-qPCR analysis of ribosome-associated RUVBL1/2 mRNA in vector- and YTHDF1-overexpressing DLD1 and HCT116 cells. B, Enrichment of RUVBL1/2 mRNA in < 40S, 40S, 60S, 80S, and polysomes from HCT116 cells with or without YTHDF1 overexpression. C and D, Colorectal cancer cells overexpressing wildtype YTHDF1 or mutant YTHDF1 were transfected with pmirGLO-RUVBL1 ( C ) or pmirGLO-RUVBL2 ( D ) containing respective 3′UTR sequences, followed by luciferase assays. E, pmirGLO-RUVBL1/2-mutant reporters with mutated m 6 A sites (RRACH to TTTCT) in the 3′UTR region demonstrated decreased luciferase activity. F, RUVBL1/2 coimmunoprecipitation and mass spectrometry for identification of common interacting proteins. G, Pathway enrichment analysis [gene ontology (GO), GSEA-KEGG] of interacting partners of RUVBL1/2. H, Coimmunoprecipitation by anti-YTHDF1 verified binding of YTHDF1 to RUVBL1/2. I, Coimmunoprecipitation using recombinant YTHDF1 and RUVBL1/2 confirmed direct protein–protein interplay between YTHDF1 and RUVBL1/2. J, Colocalization of RUVBL1/2 and YTHDF1 in HCT116 cells was determined by immunofluorescence staining. Student t test ( A , B , and E ) and one-way ANOVA ( C and D ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Techniques Used: Plasmid Preparation, Over Expression, Mutagenesis, Transfection, Luciferase, Activity Assay, Mass Spectrometry, Binding Assay, Recombinant, Immunofluorescence, Staining
Figure Legend Snippet: RUVBL1/2 knockout abrogated YTHDF1-induced translation initiation and oncogenic signaling. A, Left, polysome profiling of HCT116 cells with overexpression of YTHDF1 with or without knockout of RUVBL1/2. Right, Western blot of ribosomal fractions (<40S, 40S, 60S, 80S and polysomes). B, Stress granules (SG) were determined by immunofluorescence staining of TIA1-related protein (TIAR). C, HPG protein incorporation assay for the detection of nascent protein synthesis by immunofluorescence staining. D, Puromycin incorporation assay of protein synthesis. E, Ribo-seq of YTHDF1-overexpressing HCT116 cells with or without RUVBL1/2 knockout, following GSEA-KEGG pathway enrichment analysis. F, Effect of RUVBL1/2 knockout on the translation efficiency of MAP3K2, MAP3K7, MAPK8IP1, and ETS2 in HCT116 cells with YTHDF1 overexpression. G, Western blot of MAPK and PI3K-Akt signaling markers. One-way ANOVA ( B and C ). ***, P < 0.001; ****, P < 0.0001.
Techniques Used: Knock-Out, Over Expression, Western Blot, Immunofluorescence, Staining
Figure Legend Snippet: Pharmacological RUVBL1/2 inhibitor inhibits the growth of YTHDF1-overexpressing colorectal cancer cells. A, Structure of a RUVBL1/2 complex inhibitor, CB6644. B, Forty-eight hours-IC 50 values indicated that CB6644 preferentially inhibited the growth of DLD1 and HCT116 cells with YTHDF1 overexpression. C, CB6644 preferentially impaired colony formation capacity in YTHDF1-overexpressing DLD1 and HCT116 cells (7–14 days). D, CB6644 (0.5 µmol/L for DLD1; 0.1 µmol/L for HCT116, 24 hours) abrogated suppressive effect of YTDHF1 overexpression on apoptosis. Puromycin (0.5 µg/mL, 24 hours) was used as positive control. E, Treatment of DLD1 cells with CB6644 (0.5 µmol/L, 36 hours), followed by coimmunoprecipitation to analyze their interactions with YTHDF1. F, Interaction between YTHDF1 and EIF3K or EIF4A after treatment with CB6644 in DLD1 cells (0.5 µmol/L, 36 hours). G, Effect of CB6644 on protein translation in DLD1 cells, as assessed by puromycin incorporation assay (0.5 µmol/L, 6 hours). H, DLD1 cells expressing sgRUVBL1 or sgRUVBL2 were overexpressed with wildtype or ATPase-dead mutant RUVBL1 or RUVBL2, respectively. Coimmunoprecipitation was performed with anti-YTHDF1 to determine its interaction with RUVBL1/2, EIF3K, and EIF4A. I, Effect of ATPase-dead mutant RUVBL1 or RUVBL2 on protein translation in DLD1 cells compared with wildtype counterparts. One-way ANOVA ( E and F ). ****, P < 0.0001.
Techniques Used: Over Expression, Positive Control, Expressing, Mutagenesis
Figure Legend Snippet: In vivo efficacy of RUVBL1/2 inhibitors or vesicle-like nanoparticle-encapsulated siRUVBL1/2. A, DLD1 vector- or YTHDF1-overexpressing xenografts were treated with CB6644 (25 mg/kg, i.t.; arrows). B, HCT116 vector- or YTHDF1-overexpressing xenografts were treated with CB6644 (25 mg/kg, i.t.; arrows). C, Ki67 staining of DLD1 xenografts treated with CB6644. D, Structure of si-RUVBL1/2 encapsulated by VNPs. E, VNP-siRUVBL1/2 knockdown efficiency was confirmed in HCT116 cells in vitro . F, Effect of VNP-siRUVBL1/2 (2 mg/kg, i.t.; arrows) on DLD1 xenografts with or without YTHDF1 overexpression. G, Effect of VNP-siRUVBL1/2 (2 mg/kg, i.t.; arrows) on HCT116 xenografts with or without YTHDF1 overexpression. H, Ki67 staining of DLD1 xenografts treated with VNP-siRUVBL1/2. I, Schematic diagram showing the mechanism of RUVBL1/2 blockade in YTHDF1-expressing cells. RUVBL1/2 forms a complex with YTHDF1 and associated translation initiation factors, which is essential for YTHDF1-induced protein translation and oncogenic signaling. RUVBL1/2 themselves are targets of YTHDF1, forming a feedforward circuitry that boosts translation in colorectal cancer. RUVBL1/2 inhibition arrested translation by YTHDF1 and abrogated YTHDF1-induced oncogenic signaling and tumorigenesis. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ( D and I, Created with BioRender.com .)
Techniques Used: In Vivo, Plasmid Preparation, Staining, Knockdown, In Vitro, Over Expression, Expressing, Inhibition

